Market Indices
Latest News
 |
Spruce Biosciences, Inc. (SPRB) earnings is schedule to release on 2025-04-02. Following... April 1, 2025 SPRB -7.51% |
| ||
| ||
| ||
|
Price Targets
Gaurav Mehta from Industrial Alliance Securities issued a price target of $1.25 for SACH on 2025-03-28 11:13:23.The adjusted price target was set to $1.25.At the time of the announcement,...
March 28, 2025 SACH 0.00%
from Roth Capital issued a price target of $5.40 for MGRM on 2025-03-18 11:46:08.The adjusted price target was set to $5.40.At the time of the announcement, MGRM...
March 18, 2025 MGRM 0.00%
from Industrial Alliance Securities issued a price target of $1.75 for ASRT on 2025-03-14 11:03:06.The adjusted price target was set to $1.75.At the time of the announcement,
March 18, 2025 ASRT -2.05%
from Morgan Stanley issued a price target of $5.00 for TSVT on 2025-03-14 10:52:55.The adjusted price target was set to $5.00.At the time of the announcement, TSVT...
March 18, 2025 TSVT 0.20%
Market Movers
| Top Gainers (%) | |||||||||||||||||||
| GATE Marblegate Acquisition Co | 36.05
83.83% | ||||||||||||||||||
| EGRX Eagle Pharmaceuticals, In | 1.55
58.16% | ||||||||||||||||||
| NUTX Nutex Health, Inc. | 71.40
51.82% | ||||||||||||||||||
| HYMCW Hycroft Mining Holding Co | 0.00
44.44% | ||||||||||||||||||
| VERU Veru Inc. | 0.64
30.54% | ||||||||||||||||||
| ADAP Adaptimmune Therapeutics | 0.25
26.90% | ||||||||||||||||||
| ADAG Adagene Inc. | 1.82
19.74% | ||||||||||||||||||
| CMPX Compass Therapeutics, Inc | 2.24
17.89% | ||||||||||||||||||
Annual/Quarterly Reports Summary
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
November 6, 2024 AIP 1.74%
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
November 6, 2024 EOSEW 13.33%
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
November 6, 2024 EOSE 6.08%
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
November 5, 2024 STOK -6.32%
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
November 5, 2024 BSVN 1.16%